Global Oncology Partnering 2010-2016: Deal Trends, Players and Financial Deals and Agreements Entered into by the World's Leading Companies - Research and Markets

May 11, 2016, 14:20 ET from Research and Markets

DUBLIN, May 11, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Oncology Partnering 2010-2016: Deal trends, players and financials" report to their offering.

     (Logo: )

The report provides a detailed understanding and analysis of how and why companies enter oncology partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors oncology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest oncology agreements announced in the healthcare sector.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Oncology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Oncology deals.

The report presents financial deal terms values for Oncology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

Report scope

  • Trends in oncology dealmaking in the biopharma industry since 2010
  • Analysis of oncology deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 3,500 oncology deal records
  • The leading oncology deals by value since 2010

In Global Oncology Partnering 2010-2016: Deal trends, players and financials, the available deals are listed by:  

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Trends in Oncology dealmaking

Chapter 3 Financial deal terms for Oncology partnering

Chapter 4 Leading Oncology deals and dealmakers

Chapter 5 Oncology contract document directory

Chapter 6 Oncology dealmaking by therapeutic target

For more information visit

Media Contact:
Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets